• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Prothrombotic disturbances of hemostasis of patients with severe COVID-19: A prospective longitudinal observational study.

作者信息

Hardy Michaël, Michaux Isabelle, Lessire Sarah, Douxfils Jonathan, Dogné Jean-Michel, Bareille Marion, Horlait Geoffrey, Bulpa Pierre, Chapelle Céline, Laporte Silvy, Testa Sophie, Jacqmin Hugues, Lecompte Thomas, Dive Alain, Mullier François

机构信息

Université catholique de Louvain, CHU UCL Namur, Hematology Laboratory, Namur Thrombosis and Hemostasis Center (NTHC), Namur Research Institute for Life Sciences (NARILIS), Yvoir, Belgium; Université catholique de Louvain, CHU UCL Namur, Anesthesiology Department, Namur Thrombosis and Hemostasis Center (NTHC), Namur Research Institute for Life Sciences (NARILIS), Yvoir, Belgium.

Université catholique de Louvain, CHU UCL Namur, Department of Intensive Care, Yvoir, Belgium.

出版信息

Thromb Res. 2021 Jan;197:20-23. doi: 10.1016/j.thromres.2020.10.025. Epub 2020 Oct 24.

DOI:10.1016/j.thromres.2020.10.025
PMID:33161283
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7585359/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/48b6/7585359/68bb028b6c3b/gr2_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/48b6/7585359/76a5edfd05a6/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/48b6/7585359/68bb028b6c3b/gr2_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/48b6/7585359/76a5edfd05a6/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/48b6/7585359/68bb028b6c3b/gr2_lrg.jpg

相似文献

1
Prothrombotic disturbances of hemostasis of patients with severe COVID-19: A prospective longitudinal observational study.重症新型冠状病毒肺炎患者止血的血栓前状态紊乱：一项前瞻性纵向观察研究。
Thromb Res. 2021 Jan;197:20-23. doi: 10.1016/j.thromres.2020.10.025. Epub 2020 Oct 24.
2
Evaluation of COVID-19 coagulopathy; laboratory characterization using thrombin generation and nonconventional haemostasis assays.新型冠状病毒病凝血功能障碍的评估；应用血栓生成和非传统止血检测进行实验室特征描述。
Int J Lab Hematol. 2021 Feb;43(1):123-130. doi: 10.1111/ijlh.13329. Epub 2020 Sep 5.
3
COVID-19-related laboratory coagulation findings.与 COVID-19 相关的实验室凝血发现。
Int J Lab Hematol. 2021 Jul;43 Suppl 1(Suppl 1):36-42. doi: 10.1111/ijlh.13547.
4
Thromboelastometry as a supplementary tool for evaluation of hemostasis in severe sepsis and septic shock.血栓弹力图作为评估严重脓毒症和脓毒性休克患者止血功能的辅助工具。
Acta Anaesthesiol Scand. 2014 May;58(5):525-33. doi: 10.1111/aas.12290. Epub 2014 Mar 3.
5
Efficacy and Safety of D-dimer, Weight, and Renal Function-Adjusted Thromboprophylaxis in Patients with Coronavirus Disease 2019 (COVID-19).D-二聚体、体重及肾功能调整的血栓预防措施在2019冠状病毒病（COVID-19）患者中的疗效与安全性
Semin Thromb Hemost. 2021 Jun;47(4):436-441. doi: 10.1055/s-0040-1722309. Epub 2021 Jan 22.
6
Coronavirus Disease 2019, Prothrombotic Factors, and Venous Thromboembolism.2019冠状病毒病、血栓形成前因素与静脉血栓栓塞症
Semin Thromb Hemost. 2020 Oct;46(7):772-776. doi: 10.1055/s-0040-1710337. Epub 2020 May 11.
7
Level of antithrombin III, protein C, protein S and other selected parameters of coagulation and fibrinolysis in the blood of the patients with recurrent deep venous thrombosis.复发性深静脉血栓形成患者血液中抗凝血酶III、蛋白C、蛋白S水平及其他选定的凝血和纤维蛋白溶解参数
Med Sci Monit. 2002 Apr;8(4):CR263-8.
8
Disorders of hemostasis during the surgical management of severe necrotizing pancreatitis.重症坏死性胰腺炎外科治疗期间的止血障碍
Pancreas. 2004 Aug;29(2):152-6. doi: 10.1097/00006676-200408000-00010.
9
Complement activation and coagulopathy - an ominous duo in COVID19.补体激活与凝血障碍——COVID-19 中的凶险组合。
Expert Rev Hematol. 2021 Feb;14(2):155-173. doi: 10.1080/17474086.2021.1875813. Epub 2021 Jan 22.
10
Hematological findings and complications of COVID-19.COVID-19 的血液学表现及并发症。
Am J Hematol. 2020 Jul;95(7):834-847. doi: 10.1002/ajh.25829. Epub 2020 May 23.

引用本文的文献

1
Is lupus anticoagulant testing with dilute Russell's viper venom clotting times reliable in the presence of inflammation?在存在炎症的情况下，采用稀释蝰蛇毒凝血时间进行狼疮抗凝物检测是否可靠？
Res Pract Thromb Haemost. 2024 Jul 26;8(6):102536. doi: 10.1016/j.rpth.2024.102536. eCollection 2024 Aug.
2
COVID-19: Not a thrombotic disease but a thromboinflammatory disease.COVID-19：不是血栓性疾病，而是血栓炎症性疾病。
Ups J Med Sci. 2024 Jan 22;129. doi: 10.48101/ujms.v129.9863. eCollection 2024.
3
How to assess hypercoagulability in heparin-induced thrombocytopenia? Biomarkers of potential value to support therapeutic intensity of non-heparin anticoagulation.

本文引用的文献

1
Management of the thrombotic risk associated with COVID-19: guidance for the hemostasis laboratory.新型冠状病毒肺炎相关血栓形成风险的管理：止血实验室指南
Thromb J. 2020 Sep 7;18:17. doi: 10.1186/s12959-020-00230-1. eCollection 2020.
2
Evaluation of COVID-19 coagulopathy; laboratory characterization using thrombin generation and nonconventional haemostasis assays.新型冠状病毒病凝血功能障碍的评估；应用血栓生成和非传统止血检测进行实验室特征描述。
Int J Lab Hematol. 2021 Feb;43(1):123-130. doi: 10.1111/ijlh.13329. Epub 2020 Sep 5.
3
Features of severe COVID-19: A systematic review and meta-analysis.
如何评估肝素诱导的血小板减少症中的高凝状态？对支持非肝素抗凝治疗强度具有潜在价值的生物标志物。
Thromb J. 2023 Sep 19;21(1):100. doi: 10.1186/s12959-023-00546-8.
4
Inherited thrombophilia: undetected comorbidity complicating COVID-19 infection.遗传性血栓形成倾向：未被检测到的合并症使新冠病毒感染复杂化。
Am J Blood Res. 2023 Jun 15;13(3):94-103. eCollection 2023.
5
The Collateral Benefit of COVID Pandemic: Improved Pharmacological Venous Thromboembolism Prophylaxis Practices in Non-COVID Patients.新冠疫情的附带益处：非新冠患者药物性静脉血栓栓塞预防措施的改善
Int J Gen Med. 2023 Mar 23;16:1069-1079. doi: 10.2147/IJGM.S404827. eCollection 2023.
6
Serial thrombin generation and exploration of alternative anticoagulants in critically ill COVID-19 patients: Observations from Maastricht Intensive Care COVID Cohort.重症新型冠状病毒肺炎患者的系列凝血酶生成及新型抗凝剂探索：来自马斯特里赫特重症监护新型冠状病毒肺炎队列的观察结果
Front Cardiovasc Med. 2022 Oct 6;9:929284. doi: 10.3389/fcvm.2022.929284. eCollection 2022.
7
Spotlights on the latest opinions on identification, prevention, and management of newer CoV-2 variants: A roundup appraisal on innovative ideas and designer vaccines for Omicron.聚焦最新观点：新型冠状病毒变异株的鉴定、预防和管理：奥密克戎的创新性思路和设计疫苗综述评价。
Transfus Apher Sci. 2022 Dec;61(6):103499. doi: 10.1016/j.transci.2022.103499. Epub 2022 Jul 3.
8
Hereditary Thrombophilia in the Era of COVID-19.新冠疫情时代的遗传性血栓形成倾向
Healthcare (Basel). 2022 May 27;10(6):993. doi: 10.3390/healthcare10060993.
9
Immuno-Thrombotic Complications of COVID-19: Implications for Timing of Surgery and Anticoagulation.新型冠状病毒肺炎的免疫血栓并发症：对手术时机和抗凝治疗的影响
Front Surg. 2022 May 4;9:889999. doi: 10.3389/fsurg.2022.889999. eCollection 2022.
10
Don't let D-dimer fool you: Elevated D-dimer plasma levels should not imply 'hyperfibrinolysis'.别被D-二聚体误导：血浆D-二聚体水平升高并不意味着“高纤维蛋白溶解”。
Thromb Res. 2022 Jun;214:63-64. doi: 10.1016/j.thromres.2022.04.012. Epub 2022 Apr 25.
严重 COVID-19 的特征：系统评价和荟萃分析。
Eur J Clin Invest. 2020 Oct;50(10):e13378. doi: 10.1111/eci.13378. Epub 2020 Aug 29.
4
COVID-19 versus HIT hypercoagulability.COVID-19 与 HIT 高凝状态。
Thromb Res. 2020 Dec;196:38-51. doi: 10.1016/j.thromres.2020.08.017. Epub 2020 Aug 10.
5
Studies on hemostasis in COVID-19 deserve careful reporting of the laboratory methods, their significance, and their limitations.关于新冠病毒病止血方面的研究，需要对实验室方法、其意义及局限性进行详尽报道。
J Thromb Haemost. 2020 Nov;18(11):3121-3124. doi: 10.1111/jth.15061.
6
Hypofibrinolytic state and high thrombin generation may play a major role in SARS-COV2 associated thrombosis.低纤维蛋白溶解状态和高凝血酶生成可能在 SARS-COV2 相关血栓形成中起主要作用。
J Thromb Haemost. 2020 Sep;18(9):2215-2219. doi: 10.1111/jth.15016. Epub 2020 Aug 11.
7
Fibrinolysis Resistance: A Potential Mechanism Underlying COVID-19 Coagulopathy.纤维蛋白溶解抵抗：新冠病毒感染相关凝血障碍的潜在机制
Thromb Haemost. 2020 Sep;120(9):1343-1345. doi: 10.1055/s-0040-1713637. Epub 2020 Jul 9.
8
Thrombin generation measurement using the ST Genesia Thrombin Generation System in a cohort of healthy adults: Normal values and variability.在一组健康成年人中使用ST Genesia凝血酶生成系统进行凝血酶生成测量：正常值和变异性。
Res Pract Thromb Haemost. 2019 Jul 18;3(4):758-768. doi: 10.1002/rth2.12238. eCollection 2019 Oct.
9
A new assay for global fibrinolysis capacity (GFC): Investigating a critical system regulating hemostasis and thrombosis and other extravascular functions.一种用于评估整体纤维蛋白溶解能力（GFC）的新检测方法：探究调节止血、血栓形成及其他血管外功能的关键系统。
Transfus Apher Sci. 2018 Feb;57(1):118-126. doi: 10.1016/j.transci.2018.02.020. Epub 2018 Feb 20.